Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Jean‐Pierre Delord et al.|Journal of Thoracic Oncology|2019Cited by 437